Table 1.
Overview of studies evaluating prognostic role of variable PET-CT parameters in multiple myeloma
| Study | Study design | Number of patients | Time of PET/CT | Thresholds for PET-CT parameters (relevant survival parameter) |
|---|---|---|---|---|
| Bartel et al. [15] | Prospective | 239 | At diagnosis and before autologous SCT | nFL > 3 (OS and EFS), SUVmax > 3.9 (EFS*), EMD-positivity (OS* and EFS*) |
| Zamagni et al. [8] | Prospective | 192 | At diagnosis | SUVmax > 4.2 (OS and PFS), EMD-positivity (OS and PFS), nFLs > 3 (PFS*) |
| Fonti et al. [21] | Retrospective | 47 | At diagnosis, with subpopulation in relapse | MTV (OS and PFS) |
| Usmani et al. [11] | Prospective | 302 | At diagnosis and at induction day 7 | nFL > 3 on day 7 (OS and PFS) |
| Zamagni et al. [9] | Retrospective | 282 | After first line | SUVmax > 4.2 (PFS and OS), nFL > 3 (OS* and PFS*), EMD-positivity (OS* and PFS*) |
| Patriarca et al. [10] | Retrospective | 67 | Before allogeneic SCT | SUVmax > 4.2 (OS and PFS*), EMD-positivity (OS* and PFS), nFL > 1 (OS* and PFS*), |
| Beksac et al. [12] | Prospective | 139 | Before and after autologous SCT | SUVmax > 3.35 (OS), SUVmax > 4.2 (PFS) |
| Moreau et al. [22] | Prospective | 134 | After first line compared to PET at diagnosis | PET-positive versus PET-normalization (PFS and OS) |
| Davies et al. [14] | Retrospective (based on population of TT4-6 trials) | 596 | At diagnosis, during and after induction | nFL > 3 (OS, PFS) at diagnosis. Suppression of FL-signal beneficial |
| Wang et al. [16] | Retrospective | 123 | At diagnosis | SUVmax > 5.7 (OS*), EMD-positivity (OS and PFS) |
| Moon et al. [17] | Retrospective | 76 | At diagnosis | nFL > 3 (OS and PFS), EMD-positivity (OS and PFS) |
| Fonti et al. [23] | Retrospective | 47 | At diagnosis | MVT (OS and PFS), TLG (OS* and PFS*), SUVmax (OS*), nFL (OS* and PFS*) |
| Lapa et al. [18] | Retrospective | 37 | At relapse | nFL > 10 (TTP and OS), EMD (TTP and OS), SUVmax (ROC) > 18.5 (TTP) |
| Jamet et al. [19] | Retrospective | 40 | At relapse | nFL (appendicular skeleton) > 6 (OS, PFS), TLG (OS), SUVmax (ROC) > 15.9 (PFS), nFLs > 13 (PFS*) |
SCT stem cell transplantation, OS overall survival, EFS event free survival, PFS progression free survival, CRD complete response duration, TTP time to progression, nFL number of focal lesions, EMD extramedullary disease, SUV-standardized uptake value, MTV metabolic tumor volume, TLG total lesion glycolysis. *Parameter was significant only on univariate analysis